Protocol Ledger

NCT05982093 · Phase II · RECRUITING

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Interventional Phase II clinical trial protocol NCT05982093 sponsored by SOLTI Breast Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-03 Enrollment: 96 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05982093
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)96 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05982093
Protocol FieldVerified Registry Value
NCT IdentifierNCT05982093
Consolidated Lead SponsorSOLTI Breast Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment96 participants (ESTIMATED)
Registered Start Date2023-02-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI